NovoCure Limited reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 133.61 million compared to USD 132.66 million a year ago. Net loss was USD 13.12 million compared to net income of USD 9.28 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.13 compared to diluted earnings per share from continuing operations of USD 0.09 a year ago. For the nine months, sales was USD 401.82 million compared to USD 350.41 million a year ago. Net loss was USD 31.89 million compared to net income of USD 14.89 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to basic earnings per share from continuing operations of USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to diluted earnings per share from continuing operations of USD 0.14 a year ago.